Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 26Gastrointestinal 4Genitourinary 3Thoracic 1Plasma cell 1NET 1Head & Neck 1Gynecologic 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 362Glioblastoma 299Glioma 239Neuroblastoma 95Neoplasms 70Central Nervous System Neoplasms 62Astrocytoma 61Meningioma 59Breast Neoplasms 51Lung Neoplasms 46Carcinoma, Non-Small-Cell Lung 46Melanoma 40Sarcoma 35Medulloblastoma 33Meningeal Carcinomatosis 32Recurrence 31Neoplasm Metastasis 28Diffuse Intrinsic Pontine Glioma 28Prostatic Neoplasms 27Pheochromocytoma 26Paraganglioma 26Neurofibromatosis 1 26Pancreatic Neoplasms 24Ovarian Neoplasms 24Oligodendroglioma 22Ependymoma 21Osteosarcoma 20Head and Neck Neoplasms 20Spinal Cord Neoplasms 19Kidney Neoplasms 19

Interventions

silmitasertib 1Vincristine 1Temozolomide 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liposarcoma × CNS × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡